Beijing InnoVec Biotherapeutics

InnoVec Biotherapeutics is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to developing innovative gene therapy products. The company utilizes its proprietary IV-AAV platform to engineer next-generation Adeno-associated virus vectors with improved safety profiles and tissue-specific delivery capabilities. Its primary therapeutic focus includes ophthalmology, central nervous system disorders, and rare genetic diseases. The lead candidate, IV-101, is a gene therapy designed for the treatment of wet age-related macular degeneration. InnoVec has attracted significant investment from leading life science investors such as Lilly Asia Ventures and Hillhouse Capital. By combining advanced capsid engineering with robust manufacturing processes, the company aims to deliver transformative treatments for patients worldwide.